<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; governance</title>
	<atom:link href="http://www.tapanray.in/tag/governance/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Expand Market Share Unleashing Digital Health Potential For All</title>
		<link>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=expand-market-share-unleashing-digital-health-potential-for-all</link>
		<comments>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/#comments</comments>
		<pubDate>Mon, 15 Nov 2021 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[adoption]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[channel]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Share]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10609</guid>
		<description><![CDATA[“Advancement in digital health is currently restricted mainly to economically and socially privileged populations. Those having access, resources and basic digital skills, are reaping disproportionate benefits from the technology and other associated infrastructure available for this purpose. Unfortunately, underserved population, &#8230; <a href="http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/expand-market-share-unleashing-digital-health-potential-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Governance Maladies and Corporate Leadership</title>
		<link>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-governance-maladies-and-corporate-leadership</link>
		<comments>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/#comments</comments>
		<pubDate>Sun, 01 Oct 2017 23:37:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[Bioavailability]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Board]]></category>
		<category><![CDATA[centered]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[Dinesh]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[doctrine]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[maladies]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[managers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[senior]]></category>
		<category><![CDATA[shareholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thakur]]></category>
		<category><![CDATA[Theory]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[Whistleblower]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8444</guid>
		<description><![CDATA[On September 26, 2017, two media headlines related to the Indian pharma industry, possibly made many wonder &#8211; Are these some of the key reasons prompting the Government to enforce stringent and costly regulations in this sector? Above revelations came &#8230; <a href="http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-governance-maladies-and-corporate-leadership/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PE Investment In Pharma: The Changing Need Of Due Diligence</title>
		<link>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pe-investment-in-pharma-the-changing-need-of-due-diligence</link>
		<comments>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/#comments</comments>
		<pubDate>Mon, 02 May 2016 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[due diligence]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[PE]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[promoters]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7621</guid>
		<description><![CDATA[From an international perspective, a Bain &#38; Company report of April 2016 highlighted setting a new healthcare M&#38;A record in the year 2015. During this year the total deal value was over 2.5 times higher than the average annual deal value &#8230; <a href="http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma Demands Transparency, Keeping their &#8216;Black-Boxes&#8217; Tight and Safe?</title>
		<link>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe</link>
		<comments>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/#comments</comments>
		<pubDate>Mon, 28 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Black]]></category>
		<category><![CDATA[box]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[ghostwriting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revelation]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[samples]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[sponsorship]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tight]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wasteful]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2780</guid>
		<description><![CDATA[Pharmaceutical Industry across the globe wants absolute transparency in all government laws, policies, guidelines, transactions and overall governance. They also expect the trade environment should be predictable, non-manipulative and business-friendly. These expectations are indeed well justified and deserve whole-hearted support &#8230; <a href="http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
